Lenalidomide Inhibits Lymphangiogenesis in Preclinical Models of Mantle Cell Lymphoma

Kai Song1, Brett H. Herzog1, Minjia Sheng1,4, Jianxin Fu1,5,6, J. Michael McDaniel1, Jia Ruan3,6, and Lijun Xia1,2,5,6

Abstract

Lymphomas originate in and spread primarily along the lymphatic system. However, whether lymphatic vessels contribute to the growth and spreading of lymphomas is largely unclear. Mantle cell lymphoma (MCL) represents an aggressive non-Hodgkin’s lymphoma. We found that MCL exhibited abundant intratumor lymphatic vessels. Our results demonstrated that the immunomodulatory drug lenalidomide potently inhibited the growth and dissemination of MCL in a xenograft MCL mouse model, at least in part, by inhibiting functional tumor lymphangiogenesis. Significant numbers of tumor-associated macrophages expressing vascular endothelial growth factor-C were found in both human MCL and mouse MCL xenograft samples. Lenalidomide treatment resulted in a significant reduction in the number of MCL-associated macrophages. In addition, in vivo depletion of monocytes/macrophages impaired functional tumor lymphangiogenesis and inhibited MCL growth and dissemination. Taken together, our results indicate that tumor lymphangiogenesis contributes to the progression of MCL and that lenalidomide is effective in decreasing MCL growth and metastasis most likely by inhibiting recruitment of MCL-associated macrophages. Cancer Res 73(24): 7254–64. © 2013 AACR.

Introduction

Lymphomas are a heterogeneous group of lymphoid malignancies that originate in the lymphatic system (1). However, whether lymphatic vessels contribute to the growth and spreading of lymphomas is largely unclear. Increased expression of the lymphangiogenic factor, vascular endothelial growth factor-C (VEGF-C), and increased lymphatic vessel density have been found in several lymphoma subtypes, including mantle cell lymphoma (MCL), an aggressive form of lymphoma (2). MCL is the most difficult type of lymphoma to treat, which is due in part to its frequent dissemination (3). It is unclear whether and how lymphangiogenesis contributes to the growth and dissemination of MCL.

Materials and Methods

Cells and drugs

Mino cells, a well-established cell line derived from MCL patients with verified identity (19), were purchased from American Type Culture Collection (ATCC). The cell was tested (by Charles River) free of specific pathogens and maintained...
Sigma) was then slowly injected into the tumor. The incision incubated overnight at 4°C in goat serum, and 3% bovine serum albumin (BSA) in PBS and were blocked with 0.3% Triton X-100, 3% donkey serum, 3% goat serum, and 3% BSA in PBS (20) for 1 hour. After washing in PBS, sections were incubated with the appropriate secondary antibodies conjugated to Alexa Fluor (AF)–488, DyLight (DL)–549, or DL–649 (Jackson Immunoresearch). The sections were mounted with mounting medium with or without 4,6-diamidino-2-phenylindole (DAPI; Invitrogen) and analyzed with confocal scanning microscopy using a DSU spinning-disk head mounted on an Olympus IX81 inverted microscope with a Hamamatsu ORCA-R2 camera. Images were analyzed using Slidebook 5.0 (Intelligent Imaging Innovations) and are shown as maximum intensity projections of the 2-z-stacks. For quantification of positive staining with the lymphatic marker LYVE-1 and the pan-endothelial marker CD31, a minimum of 6 randomly chosen fields (×10 magnification) of each tumor region (peri, peripheral, and central region) were evaluated (22). For whole-mount staining, the fixed tissues were washed and blocked with 0.3% Triton X–100, 3% donkey serum, 3% goat serum, and 3% BSA in PBS and immunostained using the following primary antibodies: Syrian hamster anti-mouse podoplanin (clone 8.1.1) and rat anti-CD20 (clone L26; Abcam). Goat F(ab’)2 anti-Syrian hamster immunoglobulin G (IgG) conjugated to DL–649 or donkey anti-rat IgG conjugated to DL–549 were used as secondary antibodies.

**Histology and immunohistochemical staining**

Paraffin-embedded tissue sections (5 μm in thickness) were stained with hematoxylin and eosin (H&E) or were immunohistochemically stained (IHC). IHC was performed as follows: sections were deparaffinized and rehydrated, endogenous peroxidase activity was quenched with 3% H2O2 for 10 minutes, antigen retrieval was performed using antigen unmasking solution (Vector Laboratories), and nonspecific binding was blocked with nonspecific protein block (Dako) for 1 hour. The slides were incubated with primary antibody against podoplanin (clone D2–40; AngioBio), CD34 (Dako), or VEGFR-3 (Dako) at 4°C overnight. After washing, sections were incubated with anti-Syrian hamster secondary antibody conjugated to horseradish peroxidase. Immunoreactivity was visualized using a peroxidase-diaminobenzidine kit (Vector Laboratories).

**Immunoblotting**

Tumor tissue lysates were used. For immunoblotting, anti-podoplanin (clone 8.1.1), anti-Prox1 (Abcam), anti-VEGFR-2 (R&D Systems), anti-VEGFR-3 (R&D Systems), anti-CC15 (Cell Signaling), and anti-GAPDH (Cell Signaling) were each used at a dilution of 1:1,000. Horseradish peroxidase–conjugated anti-rabbit, anti-Syrian hamster, anti-goat, or anti-mouse secondary antibodies (Jackson Immunoresearch) were each used at a 1:5,000 dilution. The membranes were developed with SuperSignal West Pico Kit (Thermo Scientific).

**Real-time PCR analysis**

Total RNA was extracted from MCL xenografts or cultured Mino cells using RNeasy Plus Mini Kit (Qiagen), according to the manufacturer’s instructions. Total RNA was reversely

---

**Xenograft mouse models of MCL**

Eight-week-old male immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wj1/SzJ mice (NSG; Jackson Laboratory) were housed in a specific pathogen-free mouse facility (21). Mino cells (6 × 10^6/100 μL) were injected subcutaneously into both flanks of each NSG mouse near the inguinal lymph node regions. When palpable tumors developed (10 days after inoculation of Mino cells), the mice were randomized into 2 groups and injected intraperitoneally with either LEN (50 mg/kg) or vehicle (1% DMSO in PBS, sham treated; ref. 10) and were subsequently given a daily intraperitoneal injection of the same amount of LEN or vehicle control for 4 days (short-term treatment) or 21 days (long-term treatment), respectively. Primary tumor volume was measured and calculated as length × width^2 × 0.5. At the end of the treatment, mice were sacrificed, and tumors, adjacent lymph nodes, lungs, spleen, liver, and intestine were carefully removed for morphological analysis and immunostaining. All animal experiments were approved by the animal care and use committee of the Oklahoma Medical Research Foundation.

**Lymphangiography**

To image the lymph flow from the inguinal to axillary lymph nodes, 20 μL Evans blue dye (0.2%; Sigma) was injected into the hindlimb footpad of each mouse. Forty-five minutes after injection, the mice were sacrificed, and lymphangiography was carried out using a dissection microscope. To determine which lymphatic vessels drained the MCL implanted in the inguinal lymph nodal region, the tumor-bearing mice were anesthetized with isoflurane (E-Z anesthesia system; Euthanex Corporation). A small incision was made in the ventral side of the skin to expose the tumor. FITC-dextran (1.5 × 10^5 kDa MW; Sigma) was then slowly injected into the tumor. The incision was closed using sutures. Two hours after injection, a skin flap was made with the tumor near the inguinal lymph nodal area attached, and draining lymphatic vessels were imaged using an Olympus SZX12 dissection fluorescence microscope.

**Immunofluorescent staining**

For immunofluorescent staining of cryosections, tissues were fixed in 4% paraformaldehyde and embedded in OCT compound (Sakura Finetek). Cryosections (20 μm in thickness) were blocked with 0.3% Triton X–100, 3% donkey serum, 3% goat serum, and 3% bovine serum albumin (BSA) in PBS and incubated overnight at 4°C with the indicated combinations of the following primary antibodies: Syrian hamster anti-podoplanin (clone 8.1.1), rat anti-mouse CD31 (clone MEC13.3; BD Biosciences), rat anti-mouse CD105 (clone M7/18; eBioscience), rat anti-mouse F4/80 (Life Technologies), biotinylated rat anti-mouse CD11b (clone M1/70; BD Biosciences), biotinylated goat anti-LYVE-1 (clone RAB2125; R&D Systems), mouse anti-human CD68 (clone KP1; eBioscience), rabbit anti-VEGF-C (Abcam), and rat anti-human CD20 (clone L26; Abcam). After washing in PBS, sections were incubated with the appropriate secondary antibodies conjugated to Alexa Fluor (AF)–488, DyLight (DL)–549, or DL–649 (Jackson Immunoresearch). The sections were mounted with mounting medium with or without 4,6-diamidino-2-phenylindole (DAPI; Invitrogen) and analyzed with confocal scanning microscopy using a DSU spinning-disk head mounted on an Olympus IX81 inverted microscope with a Hamamatsu ORCA-R2 camera. Images were analyzed using Slidebook 5.0 (Intelligent Imaging Innovations) and are shown as maximum intensity projections of the z-stacks. For quantification of positive staining with the lymphatic marker LYVE-1 and the pan-endothelial marker CD31, a minimum of 6 randomly chosen fields (×10 magnification) of each tumor region (peri, peripheral, and central region) were evaluated (22). For whole-mount staining, the fixed tissues were washed and blocked with 0.3% Triton X–100, 3% donkey serum, 3% goat serum, and 3% BSA in PBS and immunostained using the following primary antibodies: Syrian hamster anti-mouse podoplanin (clone 8.1.1) and rat anti-CD20 (clone L26; Abcam). Goat F(ab’)2 anti-Syrian hamster immunoglobulin G (IgG) conjugated to DL–649 or donkey anti-rat IgG conjugated to DL–549 were used as secondary antibodies.
transcribed to cDNA using SuperScriptII Reverse Transcriptase (Life Technologies) with oligo(dT)20 primers. Real-time PCR was carried out using RT2 Fast SYBR Green Mastermix (SABiosciences) with specific primer sets 5'-GCTGTCACTCTCATTGTACTAGT-3' and 5'-TGGTTGAAATACTCTTGATGTG-3' for human CCL5 (Integrated DNA Technologies). Amplification and detection of mRNA were performed using the CFX96 Real-Time Detection System (Bio-Rad) according to the manufacturer's instructions. To standardize mRNA concentrations, transcript levels of 18S RNA were determined in parallel for each sample, and relative transcript levels were corrected by normalization based on 18S transcripts.

**Cell migration assay**

Mino cells were cultured in the presence or absence of 10 μmol/L LEN for 3 days (23). Same amounts of pretreated Mino cells (5.4 × 10^5/mL) were washed with Hank's Balanced Salt Solution and then cultured with serum-free media for 24 hours. Conditioned media was collected and added to the lower compartment of a transwell (5 μm pore size; Corning). 10^6 of starved murine macrophages, which were isolated from bone marrow of NSG mice and maintained in RPMI1640 medium containing 20% FBS and 10 ng/mL M-CSF (R&D Systems), were seeded in the upper compartment of a transwell. In some experiments, a neutralizing antibody against CCL5 or isotype control (16 μg/mL; R&D Systems) was added to the conditioned media from sham-treated Mino cells. After 4 hours at 37°C, migrated macrophages were stained and quantified.

**Macrophage depletion**

MCL tumor-bearing NSG mice were intravenously administered 100 μL plain liposomes (control) or clodronate-encapsulated liposomes (clodroplip, FormuMax), which deplete monocytes/macrophages, every 4 days for 16 days to determine whether macrophages are indispensable for tumor lymphangiogenesis. The efficiency of macrophage depletion was measured using flow cytometry of peripheral whole blood that had been stained with anti-CD115 (clone AF598; eBioscience) 5 days after initial administration of liposomes.

**Statistical analysis**

Statistical analysis was performed using Student t test. Differences were considered statistically significant at P < 0.05.

**Results**

**MCL tumors exhibit abundant intratumor lymphatic vessels**

To explore the role of lymphatic vessels in MCL development, we characterized the lymphatic vessel density of primary tumors from MCL patient samples and mouse MCL xenografts. Immunostaining for VEGFR-3 and podoplanin, which are lymphatic vessel markers, revealed abundant intratumor lymphatic vessels in human MCL samples (Fig. 1A).

To determine whether intratumor lymphatic vascular density correlates with MCL development, we analyzed different regions (peritumor, peripheral and central tumor regions, Fig. 1B) of mouse xenograft MCL tumors using antibodies to LYVE-1, podoplanin, and/or VEGFR-3. 3 lymphatic vessel markers, and CD31, a pan-endothelial marker. Our results demonstrated that MCL tumors contained increased number of LYVE-1+, podoplanin+, and CD31+ lymphatic vessels in the peri- and peripheral regions of the tumor (Fig. 1C and D and data not shown) in comparison with the lymphatic vascular density in the negative controls (Supplementary Fig. S1A and S1B), which was the mantle zone of normal nonreactive lymph nodes (24). The lymphatic vessels in the peripheral regions seemed to have open lumens (Fig. 1C; Supplementary Fig. S1C). Most lymphatic vessels were found in the tumor peripheral region (Fig. 1E), as measured by the depth of lymphatic vessel infiltration (25), and the central region rarely had any lymphatic vessels.

**LEN inhibits lymphangiogenesis in MCL**

Clinical trials have shown that LEN has significant activities in MCL (6). However, whether LEN inhibits lymphangiogenesis is unclear. Thus, we investigated whether LEN treatment affects MCL tumor lymphangiogenesis in the mouse xenograft MCL model. We observed a dramatic reduction in lymphatic vessel density (Fig. 1C and D) and lymphatic vessel depth of infiltration (Fig. 1C–E) in LEN-treated tumors as compared with sham-treated tumors. To further corroborate the effects of LEN on lymphangiogenesis in MCL, we examined the levels of lymphatic markers in MCL tumors with immunoblotting. Consistent with reduced lymphatic vessel density in MCL tumors after LEN treatment, Western blotting detected reduced levels of murine Prox-1, podoplanin, and VEGFR-3, 3 lymphatic vessels associated proteins, in LEN-treated tumor samples as compared with sham-treated samples (Fig. 1F).

**LEN treatment inhibits tumor growth and dissemination in a xenograft mouse model of MCL**

To determine whether LEN affects the progression of MCL in our MCL xenograft model, we examined development of LEN- or sham-treated tumors. Gross morphological analysis revealed that LEN treatment resulted in significant growth retardation of MCL xenografts as compared with the sham-treated group (Fig. 2A and B).

To determine whether LEN affects MCL dissemination, we injected Mino cells into the inguinal lymph nodal region (Fig. 2C) of NSG mice to determine whether the tumor cells spread to axillary lymph nodes, which drain the inguinal region. Thirty-five days after tumor cell injection, gross analysis revealed that axillary lymph nodes were significantly enlarged in sham-treated MCL tumor-bearing mice (Fig. 2D). In contrast, few LEN-treated, MCL tumor-bearing mice had enlarged axillary lymph nodes. Because the NSG mice do not have lymphocytes, the enlarged axillary lymph nodes in sham-treated mice were primarily resulted from disseminated MCL cells and infiltrated inflammatory cells as demonstrated by histology and immunofluorescence staining (Figs. 2E and F and 4B). In contrast, few tumor cells were detected in the axillary lymph nodes of LEN-treated mice. In addition, significantly more lung dissemination was found in sham-treated mice as compared with the LEN-treated group. In the sham-treated group, MCL spreading was occasionally detected in the spleen and rarely detected in other organs, such as the liver or...
gastrointestinal tract; it was not detected in these organs in LEN-treated mice (Supplementary Fig. S2).

LEN treatment results in nonfunctional tumor lymphangiogenesis

To determine the functionality of tumor lymphatic vessels, we first measured the uptake and transport of intratumor-injected FITC-dextran by lymphatic vessels. Immunofluorescence staining revealed that FITC-dextran-filled LYVE-1+ lymphatic vessels were frequently found in the sham-treated tumors. However, most lymphatic vessels did not contain FITC-dextran in LEN-treated tumors (Fig. 3A and B). Confocal imaging analyses of MCL samples demonstrated that human CD20+ tumor cells were frequently found inside lymphatic vascular structures in sham-treated but rarely in LEN-treated tumors (Fig. 3C and D). Together, these data support that LEN treatment results in nonfunctional tumor lymphangiogenesis that likely inhibits tumor cell dissemination through lymphatic vessels.

LEN inhibits MCL spreading through lymphatic vessels

We observed that MCL inoculated in the inguinal lymph nodal region often disseminated into the axillary lymph nodes (Fig. 2C–F). Lymphangiography performed with Evans blue dye demonstrated a major lymphatic vessel draining the inguinal lymph nodal region into the axillary lymph nodes (Supplementary Fig. S3). To test whether MCL cells spread through this lymphatic route, we injected FITC-dextran into the interstitial space of MCL tumors that were developed after inoculation of Mino cells in the inguinal lymph nodal region and then monitored the transport of the injected FITC-dextran. We found that, in sham-treated mice, FITC-dextran injected into the MCL tumor filled in the draining collecting lymphatic vessels that lead to the axillary lymph nodes; this did not occur in LEN-treated mice (Fig. 3E; Supplementary Fig. S4A). In addition, immunostaining revealed that CD20+ tumor cells were within or associated with LYVE-1+ tumor peripheral lymphatic vessels (Fig. 3F) and in the lymphatic sinuses of axillary lymph nodes (Supplementary Fig. S4B) of sham-treated mice but were rarely observed in these locations in LEN-treated, MCL tumor-bearing mice (Fig. 3F). Functional lymphangiography demonstrated an equivalent rate of transportation of the Evans blue dye through the collecting lymphatic vessels in LEN-treated mice nontumor-bearing mice, compared with sham-treated group (Supplementary Fig. S3). And no substantial
change was observed in lymphatic vessel density in the intestine, lung, and skin of mice treated with LEN relative to sham-treated mice (Supplementary Fig. S2). These results suggest that LEN treatment impairs functional tumor lymphangiogenesis but not the function of preexisting host lymphatic vessels. Collectively, these results support that tumor lymphatic vessels serve as an important route for MCL tumor cell spreading and that LEN inhibits this process.

LEN inhibits tumor lymphangiogenesis by decreasing the number of tumor-associated VEGF-C" macrophages

To investigate the mechanisms by which LEN affects tumor lymphangiogenesis, we first examined whether LEN affects the survival, proliferation, and motility of lymphatic endothelial cells, which are essential for lymphangiogenesis. However, despite its multiple antitumor activities, LEN did not affect these cellular activities of murine lymphatic endothelial cells in vitro (Supplementary Fig. S3). Further analyses indicate that LEN did not significantly alter the expression of genes related to lymphangiogenesis and immune cell trafficking, such as VEGFR1, VEGFR2, VEGFR3, E-selectin, P-selectin, PSGL-1, PIGF-2, and VE-cadherin (15, 26, 27), in lymphatic endothelial cells (Supplementary Fig. S6A). These results support that directly targeting lymphatic endothelial cells is not a mechanism by which LEN inhibits MCL lymphangiogenesis.

Lymphangiogenic factor VEGF-C derived from tumor-associated macrophage and/or cancer cells are essential for tumor lymphangiogenesis (28, 29). We found that VEGF-C was expressed in macrophages but not in tumor cells in human MCL samples (28.6% ± 2.6% of macrophages; Fig. 4A), suggesting that macrophages may be critical for lymphangiogenesis in MCL. Consistent with this finding, mouse MCL xenografts also contained large numbers of VEGF-C" macrophages that colocalized with the macrophage markers F4/80 and CD11b (Fig. 4B). In addition, we found that cultured Mino cells did not express VEGF-C under either normal culture condition or after CoCl2 treatment, which induces hypoxic condition (Supplementary Fig. S7A). This suggests that tumor-associated macrophages, but not tumor cells, are the major source of VEGF-C. LEN treatment resulted in reduced expression of VEGF-C mRNA in the MCL xenografts (Supplementary Fig. S7A). Immunofluorescence staining revealed that large numbers of F4/80"CD11b"VEGF-C" macrophages were detected in the peripheral regions of sham-treated but not LEN-treated tumors (Fig. 4B and C; Supplementary Fig. S7B and S7C). These results support that LEN attenuates VEGF-C expression by decreasing tumor-associated macrophages.
**LEN inhibits the recruitment of tumor-associated macrophages**

Infiltrated monocytes/macrophages play important roles in the promotion of tumor angiogenesis/lymphangiogenesis (27, 30). We then asked how LEN inhibits tumor-infiltrating macrophages. Initial semiquantitative RT-PCR analysis demonstrated that LEN did not significantly alter the expression of genes related to the recruitment of monocytes/macrophages in macrophages (Supplementary Fig. S6B). Further analyses of sham- or LEN-treated primary bone marrow–derived macrophages from NSG mice indicated that LEN did not directly affect the proliferation,
survival, and migration of macrophages either (Supplementary Fig. S8).

Tumor cells–derived factors such as chemokines, cytokines, and cytokine-like growth factors are essential for the recruitment of monocytes/macrophages (30). To determine whether LEN inhibits the potency of MCL tumor cells to attract macrophages, we performed a focused gene profiling analysis of sham- or LEN-treated MCL xenograft samples using a human SABiosciences RT² Profiler Array, which contains 84 key genes central to recruitment and/or activation of immune cells (31–33). This analysis revealed that chemokine CCL5 was ranked on top of genes that were significantly downregulated in LEN-treated samples relative to sham-treated (Fig. 4D; Supplementary Fig. S6C). We chose to focus on CCL5 for in-depth analysis because it is a key regulator for monocyte/macrophage recruitment (34, 35). Quantification of CCL5 by
real-time PCR and immunoblotting validated the gene array result (Fig. 4D and E). Consistent with this, conditioned media collected from Mino cell cultured in the presence of LEN significantly decreased the macrophage chemotaxis in a trans-well cell migration assay compared with media from sham-treated cells (Fig. 4F). Importantly, macrophage migration was significantly reduced when exposed to Mino cell-conditioned media containing a CCL5 neutralizing antibody but not control IgG (Fig. 4G) (36). These data indicate that LEN inhibits tumor lymphangiogenesis by reducing MCL cells from producing factors such as CCL5 that are important for attracting macrophages.

**Clodronate liposome–mediated macrophage depletion inhibits tumor lymphangiogenesis and retards MCL growth and spreading**

If LEN decreases MCL lymphangiogenesis by inhibiting MCL recruitment of macrophages, depleting macrophages would...
result in a similar anti-MCL effect. To test this, we depleted monocyte/macrophages in MCL tumor-bearing mice with clodronate encapsulated in liposomes (clodrolip; ref 37). Flow cytometric analysis of CD115, a monocyte/macrophage marker on peripheral blood cells, demonstrated that clodrolip treatment resulted in an 86.5% reduction in CD115+ cells (Fig. 5A). Consistent with this result, F4/80 staining in clodrolip-treated tumors demonstrated a significant reduction in the number of tumor-associated macrophages, which was accompanied by reduced tumor growth (Fig. 5B and C; Supplementary Fig. S9). A significant impairment in the function and the number of intratumor lymphatic vessels after clodrolip treatment was observed as compared with the control group (Fig. 5D–F). Moreover, clodrolip-treated mice exhibited reduced spreading of MCL xenografts into the axillary lymph nodes and lungs as compared with the control liposome treatment (Fig. 5G and H and data not shown). Together, these results indicate that clodrolip-mediated depletion of tumor-associated macrophages significantly blocks functional tumor lymphangiogenesis and subsequently impairs the growth and dissemination of MCL.

Discussion

Lymphangiogenesis during tumor growth and metastasis has been an emerging focus of vascular biology in recent years (27). However, whether and how lymphatic vessels contribute to dissemination of lymphoma remains unclear. Our study provides novel and definitive evidence to support that (i) MCLs in preclinical models have heightened lymphangiogenesis compared with the mantle zone of normal lymph nodes; (ii) LEN attenuates lymphatic spreading by reducing functional lymphangiogenesis; and (iii) the anti-lymphangiogenic mechanisms of LEN are, at least partly, mediated by reducing the number of tumor-infiltrating macrophages and their production of VEGF-C. To our knowledge, this is the first report on the novel therapeutic anti-lymphangiogenic mechanism of LEN in lymphoma and highlights the potential pathogenic role of lymphangiogenesis in lymphoma progression and dissemination.

Anti-lymphangiogenic agents may have therapeutic potential in a variety of malignancy types. Currently, anti-lymphatic strategies target primarily the signaling induced by VEGF-C and its receptor, VEGFR-3. A VEGFR-3–targeting monoclonal antibody, IMC-3C5, has recently entered phase I clinical trials for patients with advanced solid tumors that are refractory to standard therapy or for which no standard therapy is available (15). Blocking antibodies to neuropilin-2, a coreceptor for VEGF-C, have also shown efficacy in reducing lymphangiogenesis and lung metastasis in animal models (38, 39). LEN (Revlimid), a derivative of thalidomide, was initially introduced asone, and bortezomib, LEN has proven effective in the treat-

Discussion

Lymphangiogenesis during tumor growth and metastasis has been an emerging focus of vascular biology in recent years (27). However, whether and how lymphatic vessels contribute to dissemination of lymphoma remains unclear. Our study provides novel and definitive evidence to support that (i) MCLs in preclinical models have heightened lymphangiogenesis compared with the mantle zone of normal lymph nodes; (ii) LEN attenuates lymphatic spreading by reducing functional lymphangiogenesis; and (iii) the anti-lymphangiogenic mechanisms of LEN are, at least partly, mediated by reducing the number of tumor-infiltrating macrophages and their production of VEGF-C. To our knowledge, this is the first report on the novel therapeutic anti-lymphangiogenic mechanism of LEN in lymphoma and highlights the potential pathogenic role of lymphangiogenesis in lymphoma progression and dissemination.

Anti-lymphangiogenic agents may have therapeutic potential in a variety of malignancy types. Currently, anti-lymphatic strategies target primarily the signaling induced by VEGF-C and its receptor, VEGFR-3. A VEGFR-3–targeting monoclonal antibody, IMC-3C5, has recently entered phase I clinical trials for patients with advanced solid tumors that are refractory to standard therapy or for which no standard therapy is available (15). Blocking antibodies to neuropilin-2, a coreceptor for VEGF-C, have also shown efficacy in reducing lymphangiogenesis and lung metastasis in animal models (38, 39). LEN (Revlimid), a derivative of thalidomide, was initially introduced asone, and bortezomib, LEN has proven effective in the treat-

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors’ Contributions

Conception and design: K. Song, B.H. Herzog, J. Ruan, L. Xia Development of methodology: K. Song, B.H. Herzog, J. Fu Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): K. Song, B.H. Herzog, M. Sheng, J. Michael McDaniel, J. Ruan
Anti-Lymphangiogenesis by Lenalidomide in MCL

Grants Support
This work was supported by grants from the NIH (GM103441 and HL085607), Chinese National Natural Science Foundation (30928010. L. Xia); ASCO Career Development Award and NIH grant K08HL091347 (J. Ruan); Jiangsu Provincial Special Program of Medical Science (BL2013065), Jiangsu Province’s Key Medical Center (ZX201102. L. Xia, J. Fu, and J. Ruan).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 12, 2013; revised September 13, 2013; accepted October 7, 2013; published OnlineFirst October 24, 2013.

References
Correction: Lenalidomide Inhibits Lymphangiogenesis in Preclinical Models of Mantle Cell Lymphoma

In this article (Cancer Res 2013;73:7254–64), which was published in the December 15, 2013, issue of Cancer Research (1), Dr. Hong Chen has been added as an author. The author list should read as follows:

Kai Song, Brett H. Herzog, Minjia Sheng, Jianxin Fu, J. Michael McDaniel, Hong Chen, Jia Ruan, and Lijun Xia.

Dr. Chen’s contributions to the article are as follows: Development of methodology; Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.).

Reference
Lenalidomide Inhibits Lymphangiogenesis in Preclinical Models of Mantle Cell Lymphoma

Kai Song, Brett H. Herzog, Minjia Sheng, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-13-0750

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2013/10/24/0008-5472.CAN-13-0750.DC1

Cited articles
This article cites 45 articles, 15 of which you can access for free at:
http://cancerres.aacrjournals.org/content/73/24/7254.full.html#ref-list-1

Citing articles
This article has been cited by 6 HighWire-hosted articles. Access the articles at:
/content/73/24/7254.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.